Phospholipase D1 Attenuation Therapeutics Promotes Resilience against Synaptotoxicity in 12-Month-Old 3xTg-AD Mouse Model of Progressive Neurodegeneration
International Journal of Molecular Sciences · 08.02.2023 · 24 (4) · 3372
DOI: 10.3390/ijms24043372 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.02.2023. Verfasst von Chandramouli Natarajan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-1045, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Alzheimer's Association, Alzheimer’s Association.
Abstract (Originalsprache)
Abrogating synaptotoxicity in age-related neurodegenerative disorders is an extremely promising area of research with significant neurotherapeutic implications in tauopathies including Alzheimer’s disease (AD). Our studies using human clinical samples and mouse models demonstrated that aberrantly elevated phospholipase D1 (PLD1) is associated with amyloid beta (Aβ) and tau-driven synaptic dysfunction and underlying memory deficits. While knocking out the lipolytic PLD1 gene is not detrimental to survival across species, elevated expression is implicated in cancer, cardiovascular conditions and neuropathologies, leading to the successful development of well-tolerated mammalian PLD isoform-specific small molecule inhibitors. Here, we address the importance of PLD1 attenuation, achieved using repeated 1 mg/kg of VU0155069 (VU01) intraperitoneally every alternate day for a month in 3xTg-AD mice beginning only from ~11 months of age (with greater influence of tau-driven insults) compared to age-matched vehicle (0.9% saline)-injected siblings. A multimodal approach involving behavior, electrophysiology and biochemistry corroborate the impact of this pre-clinical therapeutic intervention. VU01 proved efficacious in preventing in later stage AD-like cognitive decline affecting perirhinal cortex-, hippocampal- and amygdala-dependent behaviors. Glutamate-dependent HFS-LTP and LFS-LTD improved. Dendritic spine morphology showed the preservation of mushroom and filamentous spine characteristics. Differential PLD1 immunofluorescence and co-localization with Aβ were noted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-1045, USA.
- Graduate School of Biomedical Sciences, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-1045, USA.
- School of Medicine, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-1045, USA.
- Department of Neurology, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-1045, USA.
ORCID-Profile: Balaji Krishnan
Förderung
- NIA NIH HHS
- Alzheimer's Association
- Alzheimer’s Association
- National Institutes of Aging
Zitieren
APA
Natarajan, C., Cook, C., Ramaswamy, K., & Krishnan, B. (2023). Phospholipase D1 Attenuation Therapeutics Promotes Resilience against Synaptotoxicity in 12-Month-Old 3xTg-AD Mouse Model of Progressive Neurodegeneration. International Journal of Molecular Sciences, 24(4), 3372. https://doi.org/10.3390/ijms24043372
Vancouver
Natarajan C, Cook C, Ramaswamy K, Krishnan B. Phospholipase D1 Attenuation Therapeutics Promotes Resilience against Synaptotoxicity in 12-Month-Old 3xTg-AD Mouse Model of Progressive Neurodegeneration. International Journal of Molecular Sciences. 2023;24(4):3372. doi:10.3390/ijms24043372
BibTeX
@article{Natarajan2023,
author = {Natarajan, Chandramouli and Cook, Charles and Ramaswamy, Karthik and Krishnan, Balaji},
title = {Phospholipase D1 Attenuation Therapeutics Promotes Resilience against Synaptotoxicity in 12-Month-Old 3xTg-AD Mouse Model of Progressive Neurodegeneration},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {4},
pages = {3372},
doi = {10.3390/ijms24043372}
}
EUVIMED